<DOC>
	<DOCNO>NCT01351753</DOCNO>
	<brief_summary>Obesity common ( &gt; 30 % US adult ) , contribute substantial morbidity mortality , difficult treat . Partly due transient , arduous modest nature lifestyle intervention . Partly due limit efficacy safety problem exist pharmacotherapy . Only one drug , orlistat , approve long-term use obesity ; effect weight relatively small . There drug approve disease also reduce weight . One promise approach treat obesity combination therapy orlistat one agent . The investigator propose innovative approach develop new therapy obesity couple use combination therapy rigorous assessment cardiovascular safety . Vascular function quantitative surrogate clinical endpoint strongly independently link future cardiovascular event . Our hypothesis combination pharmacotherapy reduce weight improve vascular function obese human subject . The co-primary endpoint weight vascular function .</brief_summary>
	<brief_title>Drug Therapy Induced Weight Loss Improve Blood Vessel Function Subjects With Obesity</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<mesh_term>Orlistat</mesh_term>
	<criteria>Age 40 75 year Male postmenopausal female BMI â‰¥ 30 kg/m2 One major cardiovascular ( CV ) risk factor ( hypertension , dyslipidemia , impair glucose tolerance OR metabolic syndrome ) Congestive heart failure Renal impairment History bariatric surgery ( i.e . lapband , RouxenY biliopancreatic diversion ) Type I diabetes mellitus Weight loss &gt; 10 % past 6 month Recurrent nephrolithiasis Current treatment seizure disorder Hepatic cirrhosis Current use study medication Current use oral estrogen History smoking cessation past three month Current cholestasis malabsorption syndrome Planned use herbal overthecounter supplement weight loss History allergic reaction metformin , topiramate , orlistat ingredient Medical condition require continuous use phosphodiesterase inhibitor and/or inability withhold phosphodiesterase inhibitor 48 hour Participation another clinical drug study within four week prior investigation . Participation weight loss rigorous exercise program . Any disease condition opinion investigator may interfere completion study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Obesity</keyword>
	<keyword>Metabolic Syndrome X</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Impaired glucose tolerance</keyword>
</DOC>